Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06244992 · ClinicalTrials.gov registry record · Phase 1
PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Locally Advanced or Metastatic Solid Tumors, sponsored by Pyrotech Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
- 3
- Study locations
NCT06244992 is a Phase 1 study of Locally Advanced or Metastatic Solid Tumors that is actively recruiting participants, run by Pyrotech Therapeutics. The registered enrollment target is 68 participants, below the 285-participant average among 5 other Locally Advanced or Metastatic Solid Tumors trials with a reported enrollment target (76% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06244992, a Phase 1 study of Locally Advanced or Metastatic Solid Tumors, is actively recruiting participants, sponsored by Pyrotech Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
- 3
- Study locations
Study Summary
This Phase 1/2a study will explore the safety and efficacy of PTT-936, an Alpha Kinase 1 (ALPK1) activator, used alone or in combination with anti-PD-1/L1 therapy in patients with locally advanced or metastatic solid tumors. The study is divided into two parts: Phase 1 (Part A) focuses on determining the pharmaceutically active dosage range and evaluating the safety profile of PTT-936 when administered as a monotherapy. Phase 2a (Part B) will assess the safety and efficacy of PTT-936 combined with anti-PD-1/L1 therapy in patients suitable for anti- PD-1/L1 monotherapy. The study aims to understand how PTT-936, alone or in combination, impacts tumor progression and patients' overall response.
Conditions Studied
Interventions
- DRUG PTT-936
- DRUG Combination of PTT-936 and anti-PD-1/L1 therapy
Study Locations (3)
California
- Precision NextGen Oncology and Research Center - Beverly Hills
Florida
- D&H Cancer Research Center - Margate
Texas
- The START Center - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2024-01-26 |
| Est. Completion | 2026-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06244992
The ClinicalTrials.gov registry entry for NCT06244992 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 5 other Locally Advanced or Metastatic Solid Tumors trials with a reported enrollment target (76% lower). The listed sponsor is Pyrotech Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Advanced or Metastatic Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which PTT-936 is the first listed.
NCT06244992 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT06244992 about?
NCT06244992 is a clinical study titled "PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors". This Phase 1/2a study will explore the safety and efficacy of PTT-936, an Alpha Kinase 1 (ALPK1) activator, used alone or in combination with anti-PD-1/L1 therapy in patients with locally advanced or metastatic solid tumors. The study is divided into two parts: Phase 1 (Part A) focuses on determinin...
What is the current status of trial NCT06244992?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2024-01-26. Estimated completion is 2026-02-28.
What conditions does trial NCT06244992 study?
This clinical trial studies the following conditions: Locally Advanced or Metastatic Solid Tumors.
What interventions are being tested in trial NCT06244992?
The interventions under investigation include: PTT-936 (DRUG), Combination of PTT-936 and anti-PD-1/L1 therapy (DRUG).
Who is sponsoring clinical trial NCT06244992?
This trial is sponsored by Pyrotech Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06244992 being conducted?
This trial has 3 study locations across California, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced or Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of XB010 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.